Autoimmune disease clinical trials address conditions in which the immune system mistakenly attacks the body's own tissues β€” a category encompassing over 80 distinct diseases affecting approximately 8% of the global population. Shared immunological mechanisms across conditions have enabled cross-indication development: agents proven in rheumatoid arthritis (TNF inhibitors, JAK inhibitors, IL-6 inhibitors) are systematically evaluated in related conditions including ankylosing spondylitis, psoriatic arthritis, and IBD.
Cutting-edge trials investigate CAR-T cell therapy for severe refractory autoimmune diseases β€” with early results showing sustained drug-free remissions in SLE and systemic sclerosis β€” telitacicept for overlapping B-cell-driven autoimmunity, BTK inhibitors as precision tools for B-cell-mediated conditions, and tolerance induction protocols for type 1 diabetes and transplant acceptance. Precision medicine biomarkers (cytokine profiles, autoantibody panels, interferon signatures) are increasingly used to enrich trial populations.
Autoimmune trials span diverse specialists β€” rheumatologists, neurologists, gastroenterologists, nephrologists β€” reflecting the organ-system specificity of individual conditions.
Frequently Asked Questions — demyelinating autoimmune diseases cns Clinical Trials
How many clinical trials are currently recruiting for demyelinating autoimmune diseases cns?
ClinicalMetric currently tracks 1 actively recruiting clinical trials for demyelinating autoimmune diseases cns, sourced in real time from ClinicalTrials.gov. The total number of registered studies—including those not yet enrolling or in active follow-up—is 1. Trial availability changes daily as new studies open enrollment and existing ones reach capacity.
What trial phases are available for demyelinating autoimmune diseases cns?
demyelinating autoimmune diseases cns research spans Phase 3 (1 trial). Phase 1 studies evaluate safety and dosing in small groups, Phase 2 studies assess preliminary efficacy in 100–300 participants, and Phase 3 trials compare the new treatment against the standard of care in 300–3,000+ patients. Phase 4 post-approval studies monitor long-term outcomes in real-world populations.
How do I find out if I qualify for a demyelinating autoimmune diseases cns clinical trial?
Eligibility criteria for demyelinating autoimmune diseases cns trials vary by study and typically specify age range, disease stage or severity, prior treatment history, and specific diagnostic or laboratory parameters. Each listing on ClinicalMetric links to the full protocol on ClinicalTrials.gov, where inclusion and exclusion criteria are documented. Contact the sponsoring site's research coordinator directly to confirm your eligibility—your treating physician or specialist can also help identify the most appropriate trial based on your medical history and current treatment status.
Top Sponsors
Amsterdam UMC, location VUmc 1 trial
Recruiting Clinical Trials
ClinicalMetric — Independent clinical trial intelligence platform. Not affiliated with NIH, ClinicalTrials.gov, the U.S. FDA, or any pharmaceutical company, hospital, or clinical research organization. Trial data is sourced from ClinicalTrials.gov for informational purposes only and does not constitute medical advice. Do not make any treatment, enrollment, or health decisions based solely on information found here — always consult a qualified healthcare professional.
Full Disclaimer ·
Last Reviewed: April 2026 ·
Data Methodology